Zymeworks (ZYME) Projected to Announce Quarterly Earnings on Thursday

Zymeworks (NASDAQ:ZYME) is expected to post its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.5413) per share and revenue of $5.8140 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:00 PM ET.

Zymeworks (NASDAQ:ZYME) last announced its earnings results on Tuesday, March 31st. The company reported ($0.59) earnings per share (EPS) for the quarter. The business had revenue of $2.41 million for the quarter. Zymeworks had a negative return on equity of 37.97% and a negative net margin of 126.92%. On average, analysts expect Zymeworks to post $1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Zymeworks Price Performance

Shares of Zymeworks stock opened at $22.79 on Wednesday. The firm’s fifty day simple moving average is $24.10 and its 200-day simple moving average is $24.46. Zymeworks has a 12 month low of $11.51 and a 12 month high of $29.75. The stock has a market capitalization of $1.66 billion, a price-to-earnings ratio of -16.63 and a beta of 1.15.

Zymeworks announced that its Board of Directors has authorized a share buyback program on Thursday, May 14th that allows the company to buyback $125.00 million in shares. This buyback authorization allows the company to reacquire up to 7% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Citigroup restated a “buy” rating on shares of Zymeworks in a research note on Tuesday, June 30th. Wells Fargo & Company increased their target price on shares of Zymeworks from $34.00 to $37.00 and gave the stock an “overweight” rating in a research note on Tuesday, June 30th. Truist Financial raised their price target on Zymeworks from $28.00 to $31.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th. HC Wainwright reaffirmed a “buy” rating and set a $46.00 price objective on shares of Zymeworks in a research note on Wednesday, June 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zymeworks in a research report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $37.33.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of ZYME. AQR Capital Management LLC raised its position in Zymeworks by 86.0% in the first quarter. AQR Capital Management LLC now owns 48,485 shares of the company’s stock worth $577,000 after acquiring an additional 22,411 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Zymeworks by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 32,385 shares of the company’s stock worth $386,000 after purchasing an additional 1,427 shares in the last quarter. Jane Street Group LLC boosted its position in shares of Zymeworks by 487.0% during the 1st quarter. Jane Street Group LLC now owns 135,763 shares of the company’s stock worth $1,617,000 after purchasing an additional 112,636 shares in the last quarter. Creative Planning grew its stake in shares of Zymeworks by 114.8% during the 2nd quarter. Creative Planning now owns 25,389 shares of the company’s stock worth $319,000 after purchasing an additional 13,567 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in shares of Zymeworks by 1,050.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 441,690 shares of the company’s stock worth $5,543,000 after purchasing an additional 403,281 shares during the period. Institutional investors and hedge funds own 92.89% of the company’s stock.

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.